Bayesian model using non-informative priors on the headache rate was used.
We badly need the same definitions of rH, better information about pretreatment headache rate and severity, more precise information about prior acute and prophylactic treatment response and scientific data regarding the natural history of drug response.
This analysis shows that topiramate reduces the risk of an increase in headache rate; specifically, patients at higher risk of developing CM (those with ≥12 headache days at baseline) appeared to benefit most from topiramate therapy.
Although adjunctive armodafinil compared with adjunctive placebo yielded a higher headache rate (15 vs 8%%), it yielded similar (generally favorably low) rates of all-cause discontinuation (16 vs 16%%), adverse event discontinuation (4 vs 5 %), nausea (6 vs 4%%), ≥7 % weight gain (2 vs 5 %), anxiety (4 vs 3 %), insomnia (3 vs 2 %), sedation/somnolence (1 vs 1 %), and hypomania (0 vs <1 %).
Studies in Africa and Japan have shown headache rates one-third and half, respectively, that of the United States.
People with pMOH are only 0.7% of the adult population but, as might be expected, carry much more individual disability: 60.2% of their time was spent in the ictal state, a huge loss of healthy time, with headache rated severe (2.95 on the scale 1 3) and a disability burden of 13.4%.
The headache rating and duration was correlated with plasma peak concentration of mCPP occurring several hours earlier, and with the area under the curve (AUC), without differences between migraine and controls [73 75, 77], but no relation with plasma level was also reported [76].
Twenty minutes after drug intake, subjects filled in a 7-item physical symptoms rating for dry mouth, dry skin, blurred vision, sedation, nausea, dizziness, and headache (rated not present, very mild, mild, moderate, moderately severe, severe, or extremely severe) and a 17-item mood rating scale using visual analog scales for pairs of words (alert drowsy, tense relaxed, etc).
(1) Relationships between headache recurrence rate (recurrence rate) and elimination half-lives of plasma drug concentrations, Ф1B, and Ф1D. (2) Relationships between headache recurrence rate (recurrence rate) and duration time of Ф1B and Ф1D. (3) Relationships between headache recurrence rate (recurrence rate) and Ф1B and Ф1D at 6, 12, and 18 h after administration. .
Relationships between headache recurrence rate (recurrence rate) and duration time of Ф1B and Ф1D.
As for that between AUCcp and headache relief rate, relief rate increased along with AUCcp increases.
